Mad Money's Jim Cramer discusses Micron Technology and how the company gained control over inventory issues. The bears expect the company's history to repeat itself, but Cramer says this time, it feels different.» Read More
The bull market is seeing the equivalent of its first gray hairs and the proof is in Tuesday's blast of merger activity.
Nick Nelson, head of global equity strategy at UBS, says earnings is currently driving moves in share prices and expects the developed world, led by the US, to lead growth this year.
Bob Parker, senior advisor of investment, strategy and Research at Credit Suisse, says valuation of technology stocks is becoming "stretched" and there is a rotation into value stocks.
Discussing new technology in the Permian, growing market in North America, and higher earnings, with Dave Lesar, Halliburton chairman, president and CEO.
Paul Raines, GameStop CEO, discusses how its leadership in digital sales, market share, and ability to drive loyalty with rewards propels consumers to stay with the gaming store.
Mad Money host Jim Cramer breaks down the momentum many sectors saw in today's rally.
The Fast Money traders share their final trades of the day.
Discussing Xbox series "Every Street United" and pricing competition for original content, with Jonathan Weinbach, Mandalay Sports Media executive producer and senior vice president.
The Fast Money traders take a look at today's biggest market movers.
Mark Newton, Greywolf Execution Partners, looks at biotech's rebound and stabilization in the space.
CNBC's David Faber reports the latest on Valeant and Pershing Square's efforts to acquire Allergan.
Discussing the fundamental concern of management for Citigroup, with Richard Bove, Rafferty Capital.
Dan Nathan of Risk Reversal shorts Netflix's momentum. FM trader Guy Adami weighs in on the trade.
The "Fast Money" traders dissect Brian Kelly's trade on FireEye.
Headlines after the bell: T, AMGN, VMW
Former Minnesota Governor Jesse Ventura makes the case that CEO pay is "way out of line" and that we should stop cheapening the idea of physical labor. "Shark Tank" investor Kevin O'Leary and CNBC's Kate Kelly weigh in.
Providing insight on Bill Ackman and Valeant's proposed takeover of Allergan, with former SEC chairman Harvey Pitt and CNBC's Kate Kelly.
Providing instant analysis to Gilead and Amgen's quarterly numbers, with David Nelson, Belpointe Asset Management, and CNBC's Sharon Epperson and Kate Kelly.
Gilead is reporting Q1 EPS of $1.48 adj. on revenues of $5.00 billion, with CNBC's Meg Tirrell.
Amgen is reporting Q1 EPS of $1.87 ex-items on revenues of $4.52 billion, with CNBC's Meg Tirrell.